Journal
JOURNAL OF CONTROLLED RELEASE
Volume 176, Issue -, Pages 123-132Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jconrel.2013.12.019
Keywords
Red blood cells; Erythrocytes; Cell penetrating peptide; Acute lymphoblastic leukemia; Encapsulation
Funding
- NIH R01 Grant, School of Pharmacy, Fudan University & The Open Project Program of Key Lab of Smart Drug Delivery (Fudan University), Ministry of Education, China [CA114612, SDD2013-04]
- National Natural Science Foundation of China (NSFC) [81361140344]
- Tianjin Municipal Science and Technology Commission [12JCZDJC34000]
- National Key Basic Research Program of China [2011CB933100]
Ask authors/readers for more resources
Red blood cells (RBCs) based drug carrier appears to be the most appealing for protein drugs due to their unmatched biocompatability, biodegradability, and long lifespan in the circulation. Numerous methods for encapsulating protein drugs into RBCs were developed, however, most of them induce partial disruption of the cell membrane, resulting in irreversible alterations in both physical and chemical properties of RBCs. Herein, we introduce a novel method for encapsulating proteins into intact RBCs, which was meditated by a cell penetrating peptide (CPP) developed in our lab-low molecular weight protamine (LMWP). L-asparaginase, one of the primary drugs used in treatment of acute lymphoblastic leukemia (ALL), was chosen as a model protein to illustrate the encapsulation into erythrocytes mediated by CPPs. In addition current treatment of ALL using different L-asparaginase delivery and encapsulation methods as well as their associated problems were also reviewed. (C) 2013 Elsevier B. V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available